Table 3.
Type of Allergen Immunotherapy
| AIT characteristics | Frequency, n (%) |
|---|---|
| Administration schedule | |
| Pre-seasonal | 3 (3.2) |
| Pre-coseasonal | 1 (1.1) |
| Perennial | 89 (95.7) |
| Route of administration | |
| Subcutaneous | 85 (91.4) |
| Sublingual drops | 2 (2.2) |
| Sublingual tablets | 6 (6.5) |
| Type of build-up phase | |
| Conventional | 25 (26.9) |
| Grouped | 37 (39.8) |
| Rush | 29 (31.2) |
| Ultrarush | 2 (2.2) |
| Type of AIT | |
| Native SCIT | 43 (46.2) |
| Modified SCIT | 39 (41.9) |
| SLIT | 9 (9.7) |
| Not specified | 2 (2.2) |
| Specific AIT by allergen | |
| Mites | 27 (29.0) |
| Animals | 42 (45.2) |
| Pollen | 24 (25.8) |
| Molds | 10 (10.8) |
| Occupational | 1 (1.1) |
Abbreviations: AIT, allergen immunotherapy; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy.